AVEO Oncology AVEO today announced that detailed results from
an exploratory, randomized Phase 2 study evaluating the combination of
ficlatuzumab, the company's HGF inhibitory antibody, and gefitinib
compared to gefitinib monotherapy in previously untreated Asian subjects
with non-small cell lung cancer (NSCLC) were presented at the 2012
Congress of the European Society for Medical Oncology (ESMO). As
previously reported, the study did not achieve its primary endpoint;
however, the results presented at ESMO suggest that the addition of
ficlatuzumab to gefitinib may be effective in select subsets of patients.
“The insights gleaned from the Phase 2 study, along with new
pharmacodynamic data, show that inhibiting the HGF ligand may be
important in the treatment
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in